NKTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nektar Therapeutics is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive analyst sentiment and potential catalysts in its drug pipeline, the financial performance is weak, hedge funds are selling heavily, and there are no strong trading signals or recent congress trading data to support immediate action. The investor should wait for clearer financial improvements or stronger technical signals before committing funds.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 48.125, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 69.731, with key support at 64.509 and resistance at 74.953. The stock's short-term trend suggests a 40% chance of a slight decline (-0.62%) in the next day.
Analysts have raised price targets significantly, with targets ranging from $150 to $165, citing strong clinical trial results for Rezpeg.
Rezpeg's potential as a first-line treatment in atopic dermatitis and alopecia areata could drive long-term revenue growth.
No significant adverse events reported in clinical trials, enhancing investor confidence in the drug's safety profile.
Financial performance is weak, with revenue dropping by 51.13% YoY and a negative EPS of -1.
Hedge funds are selling heavily, with a 1229.84% increase in selling activity last quarter.
No recent congress trading data or influential figure activity to support the stock.
In Q3 2025, revenue dropped by 51.13% YoY to $11.79M, net income fell by 4.14% YoY to -$35.52M, and EPS declined by 29.7% YoY to -1.87. However, gross margin improved to 100%, up 22.52% YoY.
Analysts are highly bullish on Nektar, with multiple firms raising price targets significantly (e.g., $150-$165) and upgrading ratings to Buy or Outperform. The positive sentiment is driven by strong clinical trial results for Rezpeg and its potential market impact.
